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Abstract
HIV incidence estimates are used to monitor HIV-1 infection in the United States. Use of lab-
oratory biomarkers that distinguish recent from longstanding infection to quantify HIV inci-
dence rely on having accurate knowledge of the average time that individuals spend in a
transient state of recent infection between seroconversion and reaching a specified bio-
marker cutoff value. This paper describes five estimation procedures from two general sta-
tistical approaches, a survival time approach and an approach that fits binomial models of
the probability of being classified as recently infected, as a function of time since serocon-
version. We compare these procedures for estimating the mean duration of recent infection
(MDRI) for two biomarkers used by the U.S. National HIV Surveillance System for determi-
nation of HIV incidence, the Aware BED EIA HIV-1 incidence test (BED) and the avidity-
based, modified Bio-Rad HIV-1/HIV-2 plus O ELISA (BRAI) assay. Collectively, 953 speci-
mens from 220 HIV-1 subtype B seroconverters, taken from 5 cohorts, were tested with a
biomarker assay. Estimates of MDRI using the non-parametric survival approach were
198.4 days (SD 13.0) for BED and 239.6 days (SD 13.9) for BRAI using cutoff values of
0.8 normalized optical density and 30%, respectively. The probability of remaining in the
recent state as a function of time since seroconversion, based upon this revised statistical
approach, can be applied in the calculation of annual incidence in the United States.
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Introduction
Measurement of the number of new HIV-1 infections per year and the annual rate at which
incident infections occur is important for tracking HIV and monitoring transmission, for eval-
uation of preventive interventions, and for resource allocation. Application of laboratory meth-
ods to distinguish recent from non-recent HIV infection, based upon characteristics of the
antibody response early after seroconversion, has led to a less costly approach in the estimation
of HIV incidence [1]. Since the publication of a sensitive/less-sensitive testing algorithm in
1998 [2], a number of bioassays have been developed to detect recent infections [3–6]. Many of
these assays have recently received a formal evaluation of performance as an incidence assay by
the Consortium for the Evaluation and Performance of HIV Incidence Assays [7].
For future biomarker-based HIV incidence estimates using the stratified extrapolation
approach [8], the U.S. National HIV Surveillance System (NHSS) will transition from using the
Aware BED EIA HIV-1 Incidence test (BED) to the Bio-Rad avidity index (BRAI), a modifica-
tion of the HIV-1/HIV-2 plus O ELISA test, to classify infections as recent vs. non-recent. The
accuracy of new incidence estimates will depend on having an accurate estimate of the mean
duration of recent infection (MDRI) and an accurate estimate of the distribution of recency
duration from a representative sample of U.S. subtype B incident HIV infections. It is impor-
tant to estimate MDRI for both BED and BRAI using the same statistical procedures to facili-
tate bridging between NHSS historic and future trends in HIV incidence.
A critical parameter in the estimation of HIV incidence, MDRI for a given bioassay such as
BED or BRAI, is defined as the average length of time, over a fixed time T, that persons with
newly acquired infection are classified by the bioassay as having recently acquired infection.
MDRI is expressed as OT ¼
R T
0
PRðtÞdt, where PR(t) is the probability of obtaining a recent
result and t is the time since detectable infection. T was chosen to capture most of the dynamic
range of a bioassay; i.e., PR  0 for t>T [9]. Estimation of OT consists of analyzing longitudinal
data from HIV seroconverters, where standard methods, such as survival analysis or binomial
regression, must be carefully adapted to consider fluctuations of HIV-infected persons in and
out of the bioassay-defined state of recent infection and imprecisely known seroconversion
times. This report details two general approaches used to estimate ΩT and provides estimates
of the OT incidence parameter for both BED and BRAI for persons infected with subtype B, the
predominant subtype in the United States. We also describe the distribution of recency dura-
tion for application to NHSS HIV incidence data.
Materials and Methods
Biomarker data were generated from longitudinal specimens of therapy-naïve individuals from
the United States infected with HIV-1 subtype B who had known dates of last negative and
first positive HIV antibody test dates less than 365 days apart collected as part of various cohort
studies, including: plasma samples from the HIVNET HIV network for prevention trials [10],
the AIDSVAX B/B candidate vaccine phase III trial (Vax004) [11], the multicenter AIDS
cohort study (MACS) [12], and the Seroconversion Incident Panel Project (SIPP) in collabora-
tion with SeraCare Life Sciences, Inc. in Milford, MA. In addition, biomarker data were gener-
ated from commercially available seroconversion panels obtained from SeraCare Life Sciences
(previously known as Boston Biomedical Inc. (BBI)) (Table 1). Specimens were unlinked from
personal identifiers and determined not to be human subjects research by the Centers for Dis-
ease Control and Prevention.
The principles of the BED-capture enzyme immunoassay, measuring the proportion of
immunoglobulin G that is specific to HIV, and the Bio-Rad GS HIV-1/HIV-2 Plus O EIA,
measuring the avidity of maturing antibodies to bind less strongly to the antigen early after
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infection, have been described in detail elsewhere [4, 13–14]. The thresholds used to classify
recent vs. long-standing infection were 0.8 normalized optical density (OD) for BED and 30%
for BRAI [15–16].
Two general approaches were used to estimate OT: (i) survival time methods, and (ii) bino-
mial models of the probability of testing recent as a function of time since seroconversion. The
fitted models were used to calculate OT at the specified recency thresholds and within the
dynamic range of each bioassay, at T = 2 years post seroconversion. Differences in survival
time distributions by cohort were assessed using a log-rank test with a p-value adjustment for
multiple comparisons.
In the first approach, the Kaplan-Meier estimator of the survival function describing the
probability of being in the recent state as a function of time since seroconversion was estimated
by a step function using a maximum likelihood approach, after approximating entry (serocon-
version) and exit (transition from recent to non-recent) times for each subject. To use the
Kaplan-Meier estimator, the time spent in the recent state must be known or right- censored
(have a lower bound). Before application of the Kaplan-Meier estimator, seroconversion times
were approximated by the midpoints of seroconversion intervals, i.e., the time between last
HIV-negative and first HIV-positive tests. This approximation assumes the seroconversion
times were uniformly distributed within the seroconversion intervals. The times of transitions
from recent to non-recent infection were estimated using linear interpolation or regression
(see below) between measurement readings. If a person did not have a non-recent result, then
the time in the recent state was right-censored; i.e., time in the state was greater than the time
from estimated seroconversion to the subject’s last visit (lower bound for survival time). Given
the resulting set of distinct times spent in the recent state after seroconversion, the estimator
for the probability of being in the recent state at time t post-seroconversion is given by
ŜðtÞ ¼ Qti<t ni  dini , where di is the number of transitions from recent to non-recent occurring
at time ti post-seroconversion, and ni is the number of subjects in the sample at time ti after
seroconversion (the number of subjects who have not yet transitioned and not been censored
by time ti). ŜðtÞ ¼ 1 for t<t1. OT was estimated by
R T
0
SðtÞdt. The survival probability func-
tion was computed from the Kaplan-Meier step function, with probabilities given at each day
between 0 and T days. Gaps between days were filled with the probability for the last day before
the gap, and for those days with an estimated probability that included a fraction of a day, a
weighted sum of probabilities was computed for the day, with weights based upon the duration
per fraction. A correction to the Kaplan-Meier estimator was applied by classification of the
maximum observation to an event if it was censored [17]. In addition to non-parametric sur-
vival, survival times spent in the recent state, as defined above, were modelled parametrically
Table 1. Characteristics of data used in estimation of MDRI by data source. The median and interquartile range of distributions are given for the HIV-
negative seroconversion interval, i.e., time between last HIV-negative and first HIV-positive tests; the HIV-positive follow-up, reflecting the total duration of
observation after testing positive; the number of HIV-positive samples; and the HIV-positive sampling intervals or times between consecutive samples.













BBI (17, 50) BED 7 (5, 18) 7 (0, 21) 2 (1, 4) 5 (4, 11)
HIVNET (89, 380) BED, BRAI 183 (148, 195) 217 (64, 517) 4 (2, 6) 77 (50, 91)
MACS (41, 154) BED 182 (155, 192) 581 (456, 732) 4 (4, 4) 188 (161, 203)
SIPP (11, 95) BRAI 30 (21, 56) 336 (184, 605) 9 (7, 11) 30 (28, 34)
Vax004 (62, 274) BED, BRAI 184 (161, 196) 124 (65, 167) 4 (4, 5) 28 (22, 23)
All Sources (220, 953) - 180 (114, 192) 208 (65, 510) 4 (3, 5) 51 (28, 95)
doi:10.1371/journal.pone.0152327.t001
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by the Weibull distribution. The probability distribution function for the Weibull distribution
is given by gðt; a; bÞ ¼ ab ð tbÞa1expð  tb
 a
Þ, where β is the Weibull scale parameter or spread
of the distribution and α shape parameter.
Neglected in our previous estimates of MDRI [18], subjects observed often enough during
the phase when the bioassay was near the recent/non-recent threshold may exhibit multiple
fluctuations back and forth between the two states. For these subjects, predicted exit times were
computed from linear regression of the bioassay measurement values on approximated days
since seroconversion using all data between the observation prior to the time when the thresh-
old was first reached and either the first observation above after the last value below the thresh-
old or the last observation for those individuals not observed above the threshold at the end of
their follow-up. If the prediction slope was negative, time was right-censored at the observation
prior to when the threshold was first reached.
In the second adapted approach [19], the probability of testing recent was modeled by fitting
a binary value for the observed non-recent/recent classifications, instead of the original OD or
avidity value for BED and BRAI, respectively. A linear binomial regression model, assuming a
logit or inverse sigmoidal logistic parametric form for the probability of testing recent as a
function of time since seroconversion, i.e. g(p) = log(p/(1 − p)), was fit to the data using a max-
imum likelihood approach. Model goodness of fit was assessed using the AIC criterion [20].
The model form was g(PR(t)) = Sβt, where g(.) was the logit link function and Sβt the linear
predictor. The seroconversion times were approximated by the midpoints of the seroconver-
sion intervals prior to model fitting. OT was estimated by
R T
0
g1ðP b̂tÞdt using the trapezoidal
rule for 731 days (0 to T). The predictor was log-transformed time since seroconversion. Boot-
strapping was performed by sampling from subjects; 1000 replicates were computed. To
account for potential subject level clustering effect on estimates of MDRI, a random intercept
binomial model, with the logit parametric form was fit to the data using a pseudo-likelihood
technique. [21] The linear predictor is of the form Sβt + γ, where γ is the subject-specific ran-
dom effect. The minimum and maximum cluster size per subjects was 1 and 15, respectively.
In addition to this parametric approach, a generalized additive model (GAM) was fit to the
binomial data with a logit link. The additive model generalizes the linear binomial model by
modeling the expectation of testing recent as g(PR(t)) = SC(t), where SC(t) was a smooth
function of time since seroconversion, estimated non-parametrically with flexible spline terms
for the predictor [22]. The degrees of freedom determine the amount of smoothing. A cross-
validation method was used to optimize the effective number of parameters defined by the
degrees of freedom [23]. The ‘log-transformed time since seroconversion’ term was fit by using
a univariate smoothing spline with four degrees of freedom; of these, one was taken up by the
linear portion of the fit and three by the nonlinear spline portion. As with the parametric bino-
mial model, bootstrapping was performed to derive measures of accuracy.
SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA) was used to implement all
steps of the estimation methods.
Results
Collectively, 953 specimens from 220 HIV-1 subtype B seroconverters taken from 5 cohorts
were tested using either BED, BRAI, or both (Table 1, S1 and S2 Tables). The median time
between last HIV-negative and first HIV-positive specimens, based upon Western blot diag-
nostic testing criteria, was 180 (interquartile range (IQR) 114, 192) days. The median duration
of follow-up following HIV-positive diagnosis was 208 (IQR 65, 510) days; there were a median
of 4 (IQR 3, 5) specimens per subject sampled approximately every 51 (IQR 28, 95) days. The
BED and Bio-Rad Avidity Mean Recency Period for HIV-1 Subtype B
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percentage of subjects who did not enter the non-recent state during the course of their follow-
up, as defined by the bioassay threshold, was 29% (61/209) for BED and 38% (62/162) for
BRAI. There were not significant differences in the BED or BRAI probability distributions for
remaining in the recent state by cohort (p>0.05).
Most subjects show increases in HIV antibody levels over time, though there was heteroge-
neity among individual responses (Fig 1) for both BED and BRAI. The estimates for OT range
from 198.4 to 215.7 days for BED and 239.3 to 253.6 for BRAI avidity, differences of approxi-
mately 2–3 weeks between estimation methods (Table 2). The relative standard error (RSE), i.e.
standard error divided by the mean, ranged from 5.8 to 8.0% for BED and 5.4 to 7.0% for
BRAI, with the lower RSEs associated with the survival procedures or the binomial random
intercept models, suggestive of slightly better fit, but with similar dispersion observed for the
two bioassays.
Discussion
In this report we have used five estimation procedures based on two statistical approaches to
estimate the MDRI, a key parameter in estimation of population level HIV incidence, and the
distribution of time from seroconversion to non-recent classification which can be used by
NHSS to estimate the number of new HIV-1 infections for monitoring of trends in incidence at
the national and state levels. Resulting estimates of OT ranged from 198.4 to 215.7 days for
BED and 239.3 to 253.6 days for Bio-Rad avidity. These results constitute revised estimates for
the BED mean duration of recency used in the HIV-1 incidence algorithm [18] and are consis-
tent with other recently published estimates of BEDMDRI [19, 24]. Differences in OT due
to revisions will be inversely proportional to differences in estimated incidence when OT is
applied to NHSS incidence data because this parameter is in the denominator of the incidence
algorithm [20, 25–26], and will result in lower estimates of HIV-1 incidence than previously
published [27, 28]. Improved estimation methods that account for the wide variability in indi-
vidual response to antibody maturation, and specifically the potential fluctuations around the
bioassay threshold, have been implemented. In addition, we have developed a random inter-
cept model for the binomial approach to appropriately account for varying subject-level cluster
sizes. The resulting MDRIs based upon our data were 1–2 weeks shorter when estimated
from the random effects models relative to the logit models which assumed independence of
observations.
Estimation of OT in general, and our estimation work in particular, have important limita-
tions. Though we restricted our analyses to study cohorts and commercially available serocon-
verter panels of data from the United States for estimation of OT, a key difference from
previously published results, these data may not be representative of all newly diagnosed HIV-
1 subtype B infections in the United States. In addition, new diagnostic testing recommenda-
tions may lengthen MDRI by shortening the duration of time between transmission and
detected infection. Future estimates will require an adjustment to MDRI or use of new serocon-
version panel data from subjects diagnosed consistent with new HIV diagnostic testing algo-
rithms. An important assumption is that of uniformly distributed seroconversion times in the
seroconversion interval, the time from last HIV-negative to first HIV-positive tests. The
assumption of uniformly distributed seroconversion times may be reasonable for individuals
enrolled in studies that schedule visits. However, it may otherwise be possible to observe lack
of independence between testing and seroconversion time for persons motivated by suspicion
of infection or with concomitant needs for clinical care, e.g., diagnoses of STDs or pregnancy
[29–32].
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Fig 1. The probability of remaining in the recent state as a function of time since seroconversion for BED and BRAI bioassays.Model predicted
probabilities from five estimation methods are given; blue lines represent the survival methods, green dashed lines the binomial logit, and red dotted line the
GAMmethod. Subject-specific increasing trends in normalized OD or avidity are graphed in the background on the secondary vertical axis. The horizontal
dashed line represents the bioassay threshold for classification of recency/non-recency (BED threshold 0.8; BRAI threshold 30%).
doi:10.1371/journal.pone.0152327.g001
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Results from simulation studies demonstrated that the estimation methods described in this
report were robust to most data issues, e.g., duration of time between last HIV-negative and
first HIV-positive tests, frequency of HIV-positive sampling, and loss-to-follow-up [33]. How-
ever, when data issues were compounded, e.g., when both HIV-negative and HIV-positive
sampling frequency was lengthy, absolute bias increased. Although a number of methods can
be used to estimate OT, there were differences in accuracy and precision depending upon the
data quality. For example, models we implemented in estimation of MDRI that relied on a
parametric assumption or ignored within-subject correlation in the presence of varying cluster
sizes (measurements per subject) did not perform as well as the non-parametric survival
approach in the presence of increasing measurement noise with T = 2 years. Although the esti-
mates reported herein will require validation from other studies of seroconverters, the MDRI
estimates based upon the revised survival approach, 198.4 days for BED and 239.6 days for
BRAI, and more specifically, the probability of remaining in the recent state as a function of
time since seroconversion, will be applied in calculation of annual incidence in the United
States as described previously [25, 27].
Supporting Information
S1 Table. Spreadsheet with BED OD values at times since estimated time of seroconversion,
assayed for 858 specimens from 209 HIV-1 subtype B seroconverters, taken from 4 data
cohorts.
(XLSX)
S2 Table. Spreadsheet with Bio-Rad avidity values at times since estimated time of serocon-
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Table 2. Estimated days of mean duration of recent infection (MDRI) and standard error, in parenthe-
ses, for BED and BRAI incidence bioassays. A total of 858 measurements from 209 subjects of 4 cohorts
and 749 measurements from 162 subjects of 3 cohorts were used to estimate BED and BRAI MDRI, respec-
tively. Results for five estimation procedures are given.
MDRI Estimation Method BED, Cutoff 0.8 BRAI, Cutoff 30%
Non-Parametric Survival 198.4 (13.0) 239.6 (13.9)
Parametric Weibull Survival 198.8 (11.6) 239.3 (12.8)
Parametric Binomial Logit 215.7 (15.6) 253.6 (16.2)
Parametric Binomial Logit with Random Intercept 204.0 (13.1) 246.5 (13.2)
Non-Parametric GAM 213.8 (17.1) 249.7 (17.5)
doi:10.1371/journal.pone.0152327.t002
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